BR112014025189A2 - prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica - Google Patents

prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica

Info

Publication number
BR112014025189A2
BR112014025189A2 BR112014025189A BR112014025189A BR112014025189A2 BR 112014025189 A2 BR112014025189 A2 BR 112014025189A2 BR 112014025189 A BR112014025189 A BR 112014025189A BR 112014025189 A BR112014025189 A BR 112014025189A BR 112014025189 A2 BR112014025189 A2 BR 112014025189A2
Authority
BR
Brazil
Prior art keywords
heart failure
prognosis
patients
chronic heart
adverse events
Prior art date
Application number
BR112014025189A
Other languages
English (en)
Other versions
BR112014025189B1 (pt
Inventor
Struck Joachim
Gf Cleland John
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of BR112014025189A2 publication Critical patent/BR112014025189A2/pt
Publication of BR112014025189B1 publication Critical patent/BR112014025189B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica". a presente invenção refere-se ao campo de diagnósticos clínicos. particularmente, a presente invenção refere-se ao prognóstico de eventos adversos em pacientes com insuficiência cardíaca crônica estável ou estando suspeitos de ter insuficiência cardíaca crônica estável através da determinação do nível de procalcitonina (pct).
BR112014025189A 2012-04-12 2013-04-11 métodos de predizer o risco de adquirir um evento adverso e de orientação de tratamento com antibióticos em um paciente com insuficiência cardíaca crônica estável BR112014025189B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12163921 2012-04-12
PCT/EP2013/057626 WO2013153177A1 (en) 2012-04-12 2013-04-11 Prognosis of adverse events in patients with suspected chronic heart failure

Publications (2)

Publication Number Publication Date
BR112014025189A2 true BR112014025189A2 (pt) 2017-07-11
BR112014025189B1 BR112014025189B1 (pt) 2020-04-07

Family

ID=48050768

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025189A BR112014025189B1 (pt) 2012-04-12 2013-04-11 métodos de predizer o risco de adquirir um evento adverso e de orientação de tratamento com antibióticos em um paciente com insuficiência cardíaca crônica estável

Country Status (9)

Country Link
US (3) US9488659B2 (pt)
EP (1) EP2836841B1 (pt)
JP (1) JP5945063B2 (pt)
CN (1) CN104303061B (pt)
BR (1) BR112014025189B1 (pt)
HK (1) HK1203611A1 (pt)
IN (1) IN2014MN02101A (pt)
RU (1) RU2672561C2 (pt)
WO (1) WO2013153177A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104303061B (zh) * 2012-04-12 2017-05-31 B.R.A.H.M.S有限公司 患有疑似慢性心力衰竭的患者中不良事件的预后
EP2990800A1 (en) * 2014-08-29 2016-03-02 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Neprilysin as heartfailure (HF) prognostic marker
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CN105929152B (zh) * 2016-07-15 2018-06-26 安徽国科生物科技有限公司 一种用于降钙素原检测的智能检测仪
EP3570875B1 (en) * 2017-02-06 2022-07-06 Biotempt B.V. Peptide modulators of the interaction between human c-peptide and human elastin receptor for therapeutic use
CN108931658A (zh) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 用于诊断心力衰竭合并症及预后评估的血清标记物
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
RU2766252C1 (ru) * 2021-04-13 2022-02-10 федеральное государственное бюджетное образовательное учреждение высшего образования "Ульяновский государственный университет" Способ прогнозирования риска смерти у больных с хронической сердечной недостаточностью с использованием эндогенного эритропоэтина сыворотки крови

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
CN101029897A (zh) * 2007-02-09 2007-09-05 深圳市新产业生物医学工程有限公司 一种降钙素原测试试剂盒及其测试方法
DE102007009751A1 (de) * 2007-02-28 2008-09-04 B.R.A.H.M.S Aktiengesellschaft Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens
EP2101178A1 (en) * 2008-03-12 2009-09-16 BRAHMS Aktiengesellschaft Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes
US20110136161A1 (en) * 2007-08-03 2011-06-09 Joachim Struck Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease
RU2357250C1 (ru) * 2007-12-10 2009-05-27 Федеральное государственное учреждение "Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования течения хронической сердечной недостаточности
EP2419741B1 (en) 2009-04-14 2019-07-31 B.R.A.H.M.S GmbH Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
EP2284540A1 (en) * 2009-07-31 2011-02-16 BIOCRATES Life Sciences AG Method of diagnosing organ failure
CN201886025U (zh) * 2010-12-10 2011-06-29 四川迈克生物科技股份有限公司 一种快速定量检测降钙素原免疫层析试纸条
CN104303061B (zh) * 2012-04-12 2017-05-31 B.R.A.H.M.S有限公司 患有疑似慢性心力衰竭的患者中不良事件的预后

Also Published As

Publication number Publication date
IN2014MN02101A (pt) 2015-08-28
EP2836841A1 (en) 2015-02-18
RU2014145259A (ru) 2016-06-10
JP5945063B2 (ja) 2016-07-05
US20150079696A1 (en) 2015-03-19
US20160320411A1 (en) 2016-11-03
HK1203611A1 (en) 2015-10-30
CN104303061B (zh) 2017-05-31
WO2013153177A1 (en) 2013-10-17
RU2672561C2 (ru) 2018-11-16
CN104303061A (zh) 2015-01-21
US9753039B2 (en) 2017-09-05
US20170370940A1 (en) 2017-12-28
BR112014025189B1 (pt) 2020-04-07
US9488659B2 (en) 2016-11-08
EP2836841B1 (en) 2022-01-05
JP2015515630A (ja) 2015-05-28

Similar Documents

Publication Publication Date Title
BR112014025189A2 (pt) prognóstico de eventos adversos em pacientes com suspeita de insuficiência cardíaca crônica
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2011126857A3 (en) Medical diagnosis using community information
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
BR112013005810A2 (pt) métodos para reduzir a concentração de lactato no sangue
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
EA201490883A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛА К α-СИНУКЛЕИНУ ДЛЯ ДИАГНОСТИКИ ПОВЫШЕННОГО УРОВНЯ α-СИНУКЛЕИНА В МОЗГЕ
FI20116007A0 (fi) Serotoniinitason nostaminen ja diagnostisointi
BR112014004336A2 (pt) sistema e método para estimar a quantidade de interesse de um sistema de artéria / tecido / veia dinâmico
BR112013017314A2 (pt) composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
AR089067A1 (es) Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2015070001A3 (en) Compositions and methods for detecting and/or treating inflammation
SG10201600502XA (en) Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
BR112015014232A2 (pt) lesão renal aguda
PH12014501176A1 (en) Anticoagulant reversal agents
WO2013066879A3 (en) SOLUBLE UROKINASE RECEPTOR (suPAR) IN DIABETIC KIDNEY DISEASE
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2013, OBSERVADAS AS CONDICOES LEGAIS.